Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1902

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Hot Springs, Arkansas • Springdale, Arkansas • Long Beach, California + 22 more

Conditions: Hepatocellular Carcinoma
Interventions: Durvalumab, Bevacizumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 34
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more

Conditions: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
Interventions: AZD6750, rilvegostomig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: AZD0120; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more

Conditions: Lymphoma, Mantle Cell
Interventions: Acalabrutinib, Bendamustine, Rituximab, Placebo; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 65 Years and older
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 32
States / cities: Tucson, Arizona • Downey, California • Santa Monica, California + 27 more

Conditions: Hepatocellular Carcinoma
Interventions: Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 20
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 14 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Olomorasib, Pembrolizumab, Durvalumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 91
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 70 more

Conditions: Clostridioides Difficile Infection
Interventions: AZD5148, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 43
States / cities: Phoenix, Arizona • Chula Vista, California • Sacramento, California + 39 more

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 28
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 22 more

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: Tezepelumab; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Newport Beach, California • Chicago, Illinois • Chestnut Hill, Massachusetts + 1 more

Conditions: Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Interventions: Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 18 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 14
States / cities: La Jolla, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Staphylococcus Aureus
Interventions: AZD7760, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 244 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 40
States / cities: Huntsville, Alabama • Chula Vista, California • Glendale, California + 35 more

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

About this AstraZeneca sponsor directory page